Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Hogate

Nurse Practitioner, Family Wilmington, DE Nurse Practitioner

NPI 1518146752 CMS profile 11194810

1401 Foulk Rd Ste 205, Wilmington, DE 19803

Open in the dashboard

General payments

$10,140

513 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Hogate of Wilmington, DE is reported in the CMS Open Payments database as having received $10,140 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,417 120
2024 General $2,104 101
2023 General $2,159 98
2022 General $1,934 109
2021 General $1,528 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Hogate
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shannon Hogate were reported at $2,417. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shannon Hogate Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,528 $124 $35–$379 $132
2022 $1,934 $141 $44–$430 $149
2023 $2,159 $154 $49–$476 $160
2024 $2,104 $165 $51–$504 $164
2025 $2,417 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,525 79 payments
  2. GlaxoSmithKline, LLC. $1,315 79 payments
  3. Regeneron Healthcare Solutions, Inc. $1,033 48 payments
  4. BioCryst US Sales Co., LLC $1,021 38 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $916 40 payments
  6. CSL Behring $856 35 payments
  7. Pfizer Inc. $601 58 payments
  8. Genentech USA, Inc. $271 11 payments
  9. Sanofi-Aventis U.S. LLC $217 3 payments
  10. Novartis Pharmaceuticals Corporation $190 9 payments
  11. Other $2,195 113 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,572 504 payments
  2. Education $444 8 payments
  3. Honoraria $125 1 payment
Products named General payments · program years 2021–2025
  1. Orladeyo $1,021 38 payments
  2. TRELEGY ELLIPTA $894 54 payments
  3. DUPIXENT Inflammation And Immunology $721 36 payments
  4. FASENRA $638 28 payments
  5. PANZYGA $489 51 payments
  6. AIRSUPRA $480 22 payments
  7. Hizentra $468 18 payments
  8. CUTAQUIG $465 47 payments
  9. DUPIXENT Immunology $436 10 payments
  10. NUCALA $404 24 payments
  11. Other $5,874 300 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,160

Median for Nurse Practitioner: 389

Drug cost

$842,319

Median for Nurse Practitioner: $21,885

Branded share of claims

38.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 12 $574,070
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 102 $94,940
Dupixent Syringe Dupilumab Brand 12 $45,905
Breo Ellipta Fluticasone/Vilanterol Brand 24 $24,163
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 31 $23,935
Arnuity Ellipta Fluticasone Furoate Brand 41 $17,888
Advair Hfa Fluticasone Propion/Salmeterol Brand 23 $15,839
Pulmicort Flexhaler Budesonide Brand 14 $8,267
Symbicort Budesonide/Formoterol Fumarate Brand 17 $4,334
Epinephrine Generic 24 $3,868

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$117,616

Of which drugs: $79,930

Medicare patients

404

Average age 72

Services billed

4,334

289 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 55%
Diabetes 26%
Osteoporosis 22%
Depression 19%
Ischemic heart disease 17%
Chronic kidney disease 17%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
  • BioCryst US Sales Co., LLC $301
$301 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $287
$287 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $141
  • SANOFI-AVENTIS U.S. LLC $75
$216 12 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $172
$172 102 —
Hizentra
  • CSL Behring $150
$150 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record